EyePoint Pharmaceuticals (XTER:PV3) Total Liabilities : €81.49 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Total Liabilities?

EyePoint Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was €81.49 Mil.

EyePoint Pharmaceuticals's quarterly Total Liabilities declined from Jun. 2023 (€109.28 Mil) to Sep. 2023 (€95.03 Mil) and declined from Sep. 2023 (€95.03 Mil) to Dec. 2023 (€81.49 Mil).

EyePoint Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€69.91 Mil) to Dec. 2022 (€79.29 Mil) and increased from Dec. 2022 (€79.29 Mil) to Dec. 2023 (€81.49 Mil).

EyePoint Pharmaceuticals Total Liabilities Historical Data

The historical data trend for EyePoint Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Total Liabilities Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

58.18

60.15

69.91

79.29

81.49

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															79.29	71.17	109.28	95.03	81.49

EyePoint Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

EyePoint Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	58.012	+	(4.499	+	3.5527136788005E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	18.975	+	0)
	=	81.49

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	325.704	-	244.218
	=	81.49

EyePoint Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	58.012	+	(4.499	+	3.5527136788005E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	18.975	+	0)
	=	81.49

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	325.704	-	244.218
	=	81.49

EyePoint Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (XTER:PV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (XTER:PV3) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (XTER:PV3) Headlines

No Headlines